NP-C Therapeutics Overview

  • Founded
  • 2014
Founded
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

NP-C Therapeutics General Information

Description

Developer of a treatment therapy designed to treat Niemann-Pick Type C. The company's treatment therapy uses combination of three drugs which help to treat lysosomal storage diseases, enabling patients to recover severe liver disease from infiltration of the liver and respiratory failure from infiltration of the lungs.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly Angel backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • 650 Park Avenue
  • Suite 20
  • King of Prussia, PA 19406
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

NP-C Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 01-Jun-2017 00000 Completed Out of Business
1. Angel (individual) 01-Apr-2016 00000 00000 Completed Startup
To view NP-C Therapeutics’s complete valuation and funding history, request access »

NP-C Therapeutics Executive Team (3)

Name Title Board Seat Contact Info
Kasturi Haldar Ph.D Chief Scientific Officer
William Claypool MD President, Board Member & Chief Executive Officer
Dennis Willson Chairman
To view NP-C Therapeutics’s complete executive team members history, request access »

NP-C Therapeutics Board Members (1)

Name Representing Role Since
Dennis Willson Self Chairman 000 0000
To view NP-C Therapeutics’s complete board members history, request access »